Patents by Inventor In Hae HAN
In Hae HAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240190228Abstract: A battery pack mounting structure for vehicles, includes a frame side member extending in a front and rear direction on each side of a vehicle to form a chassis frame, a battery disposed to be overlapped horizontally on inside of both frame side members, and a battery case enclosing the battery therein, wherein a case side portion provided on a side of the battery case is coupled to a lower side of the frame side member.Type: ApplicationFiled: May 10, 2023Publication date: June 13, 2024Applicants: Hyundai Motor Company, Kia CorporationInventors: Won Hae LEE, Nam Ho KIM, Dae Ki JEONG, Su Jin LEE, Jun Woo PARK, Jeong Hoon HAN, Eun Bi KIM, Sun Keun PARK, Byung Joo CHUNG, Seung Hak LEE, Seung Min JEONG
-
Publication number: 20240186635Abstract: The present disclosure includes a frame side member forming a chassis frame and disposed on both sides of a vehicle in a forward-backward direction, a battery disposed to overlap inwardly from the frame side member in a horizontal direction, and a battery case surrounding the battery and coupled to the frame side member, wherein a cross section of the frame side member forms a plurality of closed spaces.Type: ApplicationFiled: May 10, 2023Publication date: June 6, 2024Applicants: Hyundai Motor Company, Kia CorporationInventors: Won Hae LEE, Nam Ho KIM, Dae Ki JEONG, Su Jin LEE, Jun Woo PARK, Jeong Hoon HAN, Eun Bi KIM, Sun Keun PARK, Byung Joo CHUNG, Seung Hak LEE, Seung Min JEONG
-
Publication number: 20240178499Abstract: A battery pack mounting structure of a vehicle includes: a frame side member of a chassis frame provided so that an upper end portion thereof is located at a position spaced downward by a predetermined reference downward distance from a step height set in consideration of ease of boarding of passengers; a battery case provided so that a battery accommodated in the battery case overlaps the frame side member in a horizontal direction thereof; a case side portion forming a side surface of the battery case, coupled to a lower side of the frame side member, and including a lower end portion aligned with a lowest ground height of the vehicle; and a case lower plate forming the battery case while supporting a lower side of the battery and disposed at a position spaced upwards from the lowest ground height.Type: ApplicationFiled: May 10, 2023Publication date: May 30, 2024Applicants: Hyundai Motor Company, Kia CorporationInventors: Won Hae LEE, Nam Ho KIM, Jun Woo PARK, Seung Min JEONG, Eun Bi KIM, Sun Keun PARK, Byung Joo CHUNG, Seung Hak LEE, Jeong Hoon HAN
-
Patent number: 11990634Abstract: A battery pack mounting structure of a vehicle includes: a frame side member of a chassis frame provided so that an upper end portion thereof is located at a position spaced downward by a predetermined reference downward distance from a step height set in consideration of ease of boarding of passengers; a battery case provided so that a battery accommodated in the battery case overlaps the frame side member in a horizontal direction thereof; a case side portion forming a side surface of the battery case, coupled to a lower side of the frame side member, and including a lower end portion aligned with a lowest ground height of the vehicle; and a case lower plate forming the battery case while supporting a lower side of the battery and disposed at a position spaced upwards from the lowest ground height.Type: GrantFiled: May 10, 2023Date of Patent: May 21, 2024Assignees: HYUNDAI MOTOR COMPANY, KIA CORPORATIONInventors: Won Hae Lee, Nam Ho Kim, Jun Woo Park, Seung Min Jeong, Eun Bi Kim, Sun Keun Park, Byung Joo Chung, Seung Hak Lee, Jeong Hoon Han
-
Patent number: 11135193Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.Type: GrantFiled: September 11, 2018Date of Patent: October 5, 2021Assignee: Enzychem Lifesciences CorporationInventors: Sei-Ryang Oh, Kyung Seop Ahn, Su Ui Lee, In Sik Shin, Na-Rae Shin, Tae-Suk Lee, JongKoo Kang, Young-Sik Jung, Yong-Hae Han, Ki Young Sohn
-
Publication number: 20210052536Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-?, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.Type: ApplicationFiled: September 2, 2020Publication date: February 25, 2021Inventors: Sei-Ryang Oh, Ok-Kyoung Kwon, Chan Mi Chun, Su Ui Lee, Kyung Seop Ahn, In Sik Shin, Seung Hyung Kim, Hye Kyung Kim, JongKoo Kang, Yong-Hae Han, Tae-Suk Lee, Ki Young Sohn
-
Patent number: 10857119Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.Type: GrantFiled: July 25, 2018Date of Patent: December 8, 2020Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of Bio Science and BiotechnologyInventors: Jae Wha Kim, Sei-Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki-Young Sohn
-
Publication number: 20200330421Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.Type: ApplicationFiled: May 28, 2020Publication date: October 22, 2020Applicants: Enzychem Lifesciences Corporation, Korea Research Institute of Bio Science and BiotechnologyInventors: Jae Wha Kim, Sei-Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki Young Sohn
-
Patent number: 10765655Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-?, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.Type: GrantFiled: December 29, 2017Date of Patent: September 8, 2020Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of BioScience and BiotechnologyInventors: Sei-Ryang Oh, Kyung Seop Ahn, Su Ui Lee, In Sik Shin, Ok-Kyoung Kwon, Seung Hyung Kim, Chan Mi Chun, Tae-Suk Lee, Yong-Hae Han, Ki Young Sohn, JongKoo Kang, Hye Kyung Kim
-
Publication number: 20190022047Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.Type: ApplicationFiled: July 25, 2018Publication date: January 24, 2019Inventors: Jae Wha KIM, Sei-Ryang OH, Kyung Seop AHN, Ho Bum KANG, Jae Min SHIN, Young Eun KO, Tae Suk LEE, Myung Hwan KIM, Jong Koo KANG, Yong-Hae HAN, Ki-Young SOHN
-
Publication number: 20190008820Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.Type: ApplicationFiled: September 11, 2018Publication date: January 10, 2019Inventors: Sei-Ryang Oh, Kyung Seop Ahn, Su Ui Lee, In Sik Shin, Na-Rae Shin, Tae-Suk Lee, JongKoo Kang, Young-Sik Jung, Yong-Hae Han, Ki Young Sohn
-
Patent number: 10098864Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.Type: GrantFiled: August 19, 2014Date of Patent: October 16, 2018Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of Bio Science and BiotechnologyInventors: Sei-Ryang Oh, Kyung Seop Ahn, Su Ui Lee, In Sik Shin, Na-Rae Shin, Tae-Suk Lee, JongKoo Kang, Young-Sik Jung, Yong-Hae Han, Ki Young Sohn
-
Publication number: 20180280336Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-?, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.Type: ApplicationFiled: December 29, 2017Publication date: October 4, 2018Inventors: Sei-Ryang OH, Kyung Seop AHN, Su Ui LEE, In Sik SHIN, Ok-Kyoung KWON, Seung Hyung KIM, Chan Mi CHUN, Tae-Suk LEE, Yong-Hae HAN, Ki Young SOHN, JongKoo KANG, Hye Kyung KIM
-
Patent number: 10058527Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.Type: GrantFiled: August 18, 2014Date of Patent: August 28, 2018Assignees: ENZYCHEM LIFESCIENCES CORPORATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Jae Wha Kim, Sei Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki-Young Sohn
-
Patent number: 9763908Abstract: The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.Type: GrantFiled: September 3, 2014Date of Patent: September 19, 2017Assignees: ENZYCHEM LIFESCIENCES CORPORATION, KOREA RESEARCH INSTITUTE OF BIONSCIENCE AND BIOTECHNOLOGYInventors: Jae Wha Kim, Sei-Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Mine Yoo, Tae-Suk Lee, JongKoo Kang, Hye Kyung Kim, Jin Soo Yook, Yong-Hae Han, Ki Young Sohn
-
Publication number: 20170042854Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-?, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.Type: ApplicationFiled: August 19, 2014Publication date: February 16, 2017Inventors: Sei-Ryang OH, Kyung Seop AHN, Su Ui LEE, In Sik SHIN, Ok-Kyoung KWON, Seung Hyung KIM, Chan Mi CHUN, Tae-Suk LEE, Yong-Hae HAN, Ki Young SOHN, JongKoo KANG, Hye Kyung KIM
-
Publication number: 20160279088Abstract: The present invention relates to compositions for promoting differentiation or proliferation of erythrocytic cells containing a monoacetyl diacylglycerol compound as an active ingredient, and pharmaceutical compositions and health functional food compositions for preventing, treating or alleviating erythrocytopenia containing the same. The monoacetyldiacylglycerol compound of the present invention is effective in promoting differentiation or proliferation of erythrocytic cells. The compound can overcome the side effects of the conventional anemia treatment medicines, and has less toxicity. Thus, the compound can be effectively used for preventing, treating or alleviating oligocythemia.Type: ApplicationFiled: September 17, 2014Publication date: September 29, 2016Inventors: Jae Wha Kim, Hai Young Jung, Ho Bum Kang, Sei-Ryang Oh, Kyung Seop Ahn, Tae-Suk Lee, JongKoo Kang, Myung Hwan Kim, Yong-Hae Han, Ki Young Sohn
-
Publication number: 20160256428Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.Type: ApplicationFiled: August 18, 2014Publication date: September 8, 2016Inventors: Jae Wha Kim, Sei Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki-Young Sohn
-
Publication number: 20160199338Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.Type: ApplicationFiled: August 18, 2014Publication date: July 14, 2016Inventors: Jae Wha KIM, Sei Ryang OH, Kyung Seop AHN, Ho Bum KANG, Beom Su PARK, Tae Suk LEE, Jong Koo KANG, Young Sik JUNG, Yong-Hae HAN, Ki-Young SOHN
-
Patent number: D886633Type: GrantFiled: May 18, 2018Date of Patent: June 9, 2020Assignee: HCT GROUP HOLDINGS LIMITEDInventor: Jung Hae Han